Peru
Tuberculosis profile
Population  2012 30 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (1.1–2) 5.1 (3.8–6.7)
Mortality (HIV+TB only) 0.051 (0.037–0.063) 0.17 (0.12–0.21)
Prevalence  (includes HIV+TB) 36 (12–73) 121 (41–243)
Incidence  (includes HIV+TB) 29 (25–32) 95 (83–108)
Incidence (HIV+TB only) 0.49 (0.43–0.55) 1.6 (1.4–1.8)
Case detection, all forms (%) 100 (92–120)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 17 653 (63) Relapse 1 735 (47)
Smear-negative 3 942 (14) Treatment after failure 527 (14)
Smear-unknown / not done 614 (2) Treatment after default 608 (17)
Extrapulmonary 5 233 (19) Other 810 (22)
Other 583 (2)      
Total new 28 025   Total retreatment 3 680  
           
Other (history unknown) 0        
Total new and relapse 29 760   Total cases notified 31 705  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio      
Age < 15      
Laboratories 2012
Smear (per 100 000 population) 4.8
Culture (per 5 million population) 11.0
Drug susceptibility testing (per 5 million population) 1.8
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 74   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 836 (18)
HIV-positive TB patients 979 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 847 (87)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 1 416  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.9 (3.6–4.2) 35 (33–37)
MDR-TB cases among notified pulmonary
TB cases
890 (820–960) 1 300 (1 200–1 400)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 14 484 (79%) 1 902 (52%) 16 386
Laboratory-confirmed MDR-TB cases 564 661 1 225
Patients started on MDR-TB treatment     1 510
Financing TB control 2013
National TB programme budget (US$ millions) 96
% Funded domestically 91%
% Funded internationally  
% Unfunded 9%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-17 Data: www.who.int/tb/data